The BOXER Ambulance, developed by ARTEC GmbH—a joint venture between KNDS and Rheinmetall—offers exceptional performance and protection for medical missions. Powered by a robust MTU V8 engine delivering up to 530 kW, it ensures maximum mobility in various operational scenarios. Its state-of-the-art chassis features single-wheel suspension with long spring travel and hydraulic dampers, minimizing crew stress during transit. The modular design includes a drive module and a mission module, providing enhanced protection for personnel. Inside, the spacious crew compartment, with an interior height of 1.85 m, allows medical staff to deliver optimal care while the flexible stretcher carrier system accommodates different casualty scenarios efficiently.
BWX Technologies, Inc. (BWXT AT) is at the forefront of innovation in additive manufacturing for advanced nuclear reactors, addressing critical challenges related to specialty materials essential for reactor components. Collaborating with Oak Ridge National Laboratory, BWXT AT has pioneered new manufacturing technologies that enable the creation of complex geometries using high-temperature alloys and refractory metals, specifically nickel-based superalloys and refractory-metal-based alloys. Their successful component-level qualification process enhances the efficiency of certifying nuclear materials, significantly advancing the capabilities of the nuclear industry. This transformative approach, validated through a cost-share program with the U.S. Department of Energy in 2018, positions BWXT AT as a leader in developing cutting-edge solutions that redefine traditional manufacturing limitations.
BWX Technologies, Inc. (BWXT) is a leader in the development of advanced medical isotopes, focusing on innovative solutions to meet critical market demands. Since entering the medical radioisotope sector in 2018 through the acquisition of Nordion’s medical isotope business, BWXT has prioritized the creation of therapeutic and theranostic radiochemicals. The company has successfully launched its Lu-177 and Ac-225 programs, addressing significant supply challenges in the industry. BWXT's proprietary Mo-99 production process, which utilizes natural molybdenum targets in commercial power reactors, not only eliminates the need for enriched uranium but also mitigates waste associated with traditional production methods. This commitment to innovation ensures that BWXT remains at the forefront of providing essential medical isotopes to enhance patient care and treatment outcomes.
Our Hurn Proving Ground offers the perfect test and evaluation facilities for Emergency Services to ensure their vehicles are fit and safe for purpose.
